# Arcus Biosciences, Inc.: overview

RCUS · NYSE · CIK 1724521 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rcus.md) · [Financials](/companies/rcus/financials.md) · [Filings](/companies/rcus/filings.md) · [Insiders](/companies/rcus/insiders.md)

Latest reported revenue: [$33.0m](/filings/0001724521-26-000044.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001724521-26-000044).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.0](/filings/0001724521-25-000116.md) | [23.0 d](/filings/0001724521-26-000009.md) | [8.0](/filings/0001724521-26-000034.md) | [8.0](/filings/0001724521-26-000044.md) | [6.0](/filings/0001724521-25-000116.md) | [11.0 d](/filings/0001724521-26-000009.md) | [7.0](/filings/0001724521-26-000034.md) | [33.0](/filings/0001724521-26-000044.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1500.0%)](/filings/0001724521-25-000116.md) | [(447.8%) d](/filings/0001724521-26-000009.md) | [(1525.0%)](/filings/0001724521-26-000034.md) | [(100.0%)](/filings/0001724521-26-000044.md) | [(2366.7%)](/filings/0001724521-25-000116.md) | [(1036.4%) d](/filings/0001724521-26-000009.md) | [(1914.3%)](/filings/0001724521-26-000034.md) | [(290.9%)](/filings/0001724521-26-000044.md) |
| Net margin | % | [(1314.3%)](/filings/0001724521-25-000116.md) | [(408.7%) d](/filings/0001724521-26-000009.md) | [(1400.0%)](/filings/0001724521-26-000044.md) | [0.0%](/filings/0001724521-26-000044.md) | [(2250.0%)](/filings/0001724521-25-000116.md) | [(963.6%) d](/filings/0001724521-26-000009.md) | [(1828.6%)](/filings/0001724521-26-000044.md) | [(275.8%)](/filings/0001724521-26-000044.md) |
| Diluted EPS | $ per share | [(1.00)](/filings/0001724521-25-000116.md) | not reported | [(1.14)](/filings/0001724521-26-000034.md) | [0.00](/filings/0001724521-26-000044.md) | [(1.27)](/filings/0001724521-25-000116.md) | not reported | [(1.02)](/filings/0001724521-26-000034.md) | [(0.72)](/filings/0001724521-26-000044.md) |
| Free cash flow | $m | [25.0 d](/filings/0001724521-25-000116.md) | [(101) d](/filings/0001724521-26-000009.md) | [(133)](/filings/0001724521-26-000034.md) | [(133) d](/filings/0001724521-26-000044.md) | [(97.0) d](/filings/0001724521-25-000116.md) | [(121) d](/filings/0001724521-26-000009.md) | [(138)](/filings/0001724521-26-000034.md) | [(119) d](/filings/0001724521-26-000044.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [383](/filings/0001724521-24-000052.md) | [38.0](/filings/0001724521-25-000040.md) | [37.0](/filings/0001724521-26-000009.md) | [51.0](/filings/0001724521-26-000009.md) | [33.0](/filings/0001724521-26-000009.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [14.1%](/filings/0001724521-24-000052.md) | [(736.8%)](/filings/0001724521-25-000040.md) | [(918.9%)](/filings/0001724521-26-000009.md) | [(647.1%)](/filings/0001724521-26-000009.md) | [(1169.7%)](/filings/0001724521-26-000009.md) |
| Net margin | % | [13.8%](/filings/0001724521-24-000052.md) | [(702.6%)](/filings/0001724521-25-000040.md) | [(829.7%)](/filings/0001724521-26-000009.md) | [(554.9%)](/filings/0001724521-26-000009.md) | [(1069.7%)](/filings/0001724521-26-000009.md) |
| Diluted EPS | $ per share | [0.71](/filings/0001724521-24-000052.md) | [(3.71)](/filings/0001724521-25-000040.md) | [(4.15)](/filings/0001724521-26-000009.md) | [(3.14)](/filings/0001724521-26-000009.md) | [(3.29)](/filings/0001724521-26-000009.md) |
| Free cash flow | $m | [(282)](/filings/0001724521-24-000052.md) | [432](/filings/0001724521-25-000040.md) | [(330)](/filings/0001724521-26-000009.md) | [(176)](/filings/0001724521-26-000009.md) | [(484)](/filings/0001724521-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rcus/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2025-02-18 | [Gilead Sciences, Inc.](/insiders/882095.md) | 10% owner | Purchase (P) | 1,363,636 | $11.00 | $15.0m | [Form 4](/filings/0001062993-25-003084.md) |
| 2024-01-29 | [Gilead Sciences, Inc.](/insiders/882095.md) | 10% owner | Purchase (P) | 15,238,095 | $21.00 | $320.0m | [Form 4](/filings/0001104659-24-008868.md) |
| 2023-06-28 | [Gilead Sciences, Inc.](/insiders/882095.md) | 10% owner | Purchase (P) | 1,010,000 | $19.26 | $19.5m | [Form 4](/filings/0001104659-23-077015.md) |
| 2021-01-31 | [Gilead Sciences Inc](/insiders/882095.md) | 10% owner | Purchase (P) | 5,650,000 | $39.00 | $220.3m | [Form 4](/filings/0001104659-21-010972.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [GILEAD SCIENCES, INC.](/funds/882095.md) | 2026-06-30 | $968.8m | 31,424,760 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $506.1m | 16,416,249 |  | Added +1,189,774 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $185.9m | 6,029,484 |  | Added +616,583 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $181.8m | 5,895,448 |  | Reduced −194,068 |
| [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $147.3m | 4,776,423 |  | Reduced −254,570 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $138.0m | 4,475,528 |  | Added +203,472 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $124.9m | 4,049,757 |  | Added +2,884,505 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $119.9m | 3,888,346 |  | Added +31,621 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $96.7m | 3,135,057 |  | Added +1,805,122 |
| [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $92.7m | 3,007,798 |  | Reduced −770,000 |

## Recent filings

[All 587 filings](/companies/rcus/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 20:12 ET | [8-K](/filings/0001724521-26-000050.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001724521-26-000050 |
| 2026-10-21 | 20:09 ET | [8-K](/filings/0001193125-26-427829.md) | 2.02 Results of operations | 0001193125-26-427829 |
| 2026-10-20 | 12:33 ET | [8-K](/filings/0001724521-26-000047.md) | 8.01 Other events | 0001724521-26-000047 |
| 2026-08-05 | 20:11 ET | [10-Q](/filings/0001724521-26-000044.md) | Quarterly report, period 2026-06-30 | 0001724521-26-000044 |
| 2026-08-05 | 20:07 ET | [8-K](/filings/0001724521-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001724521-26-000042 |
| 2026-06-12 | 20:12 ET | [8-K](/filings/0001724521-26-000037.md) | 5.07 Shareholder vote results | 0001724521-26-000037 |
| 2026-05-05 | 20:11 ET | [10-Q](/filings/0001724521-26-000034.md) | Quarterly report, period 2026-03-31 | 0001724521-26-000034 |
| 2026-05-05 | 20:09 ET | [8-K](/filings/0001724521-26-000032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001724521-26-000032 |
| 2026-04-21 | 20:06 ET | [DEF 14A](/filings/0001724521-26-000025.md) | Proxy statement, period 2026-06-11 | 0001724521-26-000025 |
| 2026-04-20 | 11:56 ET | [8-K](/filings/0001724521-26-000021.md) | 8.01 Other events | 0001724521-26-000021 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001724521-26-000009.md), filed Feb 25, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1724521
- Tickers: RCUS
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.